Another day, another healthcare fraud indictment splashed across the front page. The Department of Justice recently hauled a physician into court over a ninety-five million dollar skin substitute billing scheme, treating the case like a mob takedown. The lazy consensus in every major newsroom is simple: a greedy doctor played the system, billed for overpriced amniotic tissue grafts, and got caught. Public outrage ensues. Congress mumbles about loopholes. Everyone pretends this is an anomaly.
They are completely wrong.
This high-profile prosecution is not a sign that the healthcare system is purifying itself. It is a symptom of a broken reimbursement architecture that practically forces clinicians to weaponize billing codes just to keep the lights on. I have spent two decades watching federal regulators play whack-a-mole with pricing models they fundamentally do not understand. When you build a market based on arbitrary, convoluted fee schedules instead of actual utility, you invite gamesmanship. Then, when the inevitable happens, prosecutors slap a massive price tag on the indictment to look tough on white-collar crime while ignoring the structural design flaw that created the trap in the first place.
Let us define what these products actually are before we swallow the moral panic. Skin substitutes—often derived from human amniotic membrane, placental tissues, or engineered collagen matrices—are designed to manage hard-to-heal chronic wounds, such as diabetic foot ulcers and severe venous stasis wounds. These are not simple bandages. They are biologic scaffolds that signal cellular proliferation, reduce inflammation, and accelerate tissue granulation in patients who would otherwise face amputation.
The clinical reality is messy. A chronic diabetic foot ulcer is a ticking clock leading straight to a below-the-knee amputation, which carries a staggering five-year mortality rate worse than many cancers. When a clinician finds a biologic product that actually closes a recalcitrant wound, they use it. The problem arises because Medicare Part B and private insurers reimburse these biologic grafts based on Healthcare Common Procedure Coding System (HCPCS) codes that rely on square-centimeter pricing, often bundled or unbundled in ways that decouple the cost of the biological material from its clinical outcome.
When the pricing code rewards the sheer volume of square footage applied rather than the healing rate achieved, do not act shocked when volume goes up. That is basic economics, not a moral failure unique to medicine.
Critics love to point fingers at the manufacturers and the doctors, screaming about kickbacks and unnecessary applications. Imagine a scenario where a physician treats a patient with a massive, stalled wound that has failed standard of care for six months. They apply a high-end human tissue graft. The wound closes in four weeks. Under the current retrospective audit culture, an investigator sitting behind a desk three years later can look at the invoice, decide the biological product was marginally too expensive compared to a cheaper alternative, and label the entire clinical encounter as fraudulent billing.
That is not justice. That is hindsight bias codified into criminal law.
The indictment claims ninety-five million dollars in fraudulent billings. Let us look at how those numbers are calculated by federal investigators. They take every single claim submitted under specific codes, add them up, and label the entire sum as a loss to the taxpayer. This is financial fiction. It assumes the clinical interventions had zero value, ignoring whether the wounds healed, whether limbs were saved, and whether patients avoided hospitalization. If a patient keeps their foot because of a graft, the net savings to the healthcare ecosystem dwarfs the cost of the biologic material. Yet, the forensic accountants at the DOJ do not factor avoided amputations into their spreadsheets because saving a limb does not show up on a spreadsheet the same way a line-item invoice does.
Here is the dirty secret the federal government will never admit: the regulatory bodies set up the pricing maze. For years, the Centers for Medicare and Medicaid Services struggled to categorize cellular and tissue-based products. They created coding categories that lumped radically different biological products into broad buckets. Manufacturers and distributors exploited these pricing spreads because human incentives follow capital. If you leave a massive arbitrage opportunity sitting in the middle of a federal payment schedule, someone is going to walk through it.
Blaming the doctor at the end of the supply chain is like arresting the tollbooth operator for highway congestion.
Let us look at the fallout of this grandstanding. When the DOJ drops a nine-figure indictment on a skin substitute scheme, it sends a shockwave through every wound care clinic in America. Compliance officers panic. Risk-averse hospital legal teams immediately suspend the use of advanced biologics altogether, forcing clinicians back to standard saline gauzes and basic compression wraps that do nothing for patients with severe microvascular disease.
The real victims of this prosecution are not the insurance pools. The real victims are the diabetics sitting in clinics across the country whose doctors are now too terrified of a federal subpoena to use advanced tissue therapies. We are trading the marginal risk of overbilling for the absolute certainty of higher amputation rates.
If we want to fix this, we have to stop treating pricing disputes as criminal conspiracies. The entire fee-for-service reimbursement model for biologics needs to be detonated. We should move away from square-centimeter billing codes that penalize efficiency and move toward bundled, value-based contracts where payment is tied directly to one metric that matters: complete wound closure within twelve weeks. If a product heals the patient, pay for it. If it fails, the provider and manufacturer eat the cost.
Under a performance-based paradigm, the fraud disappears overnight because you can no longer bill for ghost tissue or excessive square footage if the wound remains open. But the regulators will not touch that solution because it requires actual competence and modernization from bureaucratic agencies that prefer the safety of filing indictments over the hard work of system redesign.
The next time you read a headline about a multi-million-dollar medical billing scandal, look past the sensationalist numbers. Ask yourself whether the system was gamed by rogue actors or if the actors simply followed the perverse incentives built by the architects of the system itself.
Stop prosecuting clinicians for navigating a broken maze, and start fixing the walls.
